ALXO vs. HRMY

Last updated Apr 1, 2026

Compare and contrast key facts about ALX Oncology Holdings Inc. (ALXO) and Harmony Biosciences Holdings, Inc. (HRMY).

Performance

ALXO vs. HRMY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ALX Oncology Holdings Inc. (ALXO) and Harmony Biosciences Holdings, Inc. (HRMY). The values are adjusted to include any dividend payments, if applicable.

ALXO vs. HRMY - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
ALXO ALX Oncology Holdings Inc.	77.43%	-32.34%	-88.78%	32.12%	-47.56%	-75.07%	93.88%
HRMY Harmony Biosciences Holdings, Inc.	-25.28%	8.75%	6.53%	-41.38%	29.22%	17.95%	-2.32%

Fundamentals

Market Cap ALXO : $108.84M HRMY : $1.64B
EPS ALXO : -$1.89 HRMY : $3.33
PB Ratio ALXO : 4.19 HRMY : 1.89
Total Revenue (TTM) ALXO : $0.00 HRMY : $868.45M
Gross Profit (TTM) ALXO : $0.00 HRMY : $670.11M
EBITDA (TTM) ALXO : -$100.09M HRMY : $238.25M

Returns By Period

In the year-to-date period, ALXO achieves a 77.43% return, which is significantly higher than HRMY's -25.28% return.

ALXO

• 1D: 4.97%
• 1M: -4.98%
• YTD: 77.43%
• 6M: 9.56%
• 1Y: 221.83%
• 3Y*: -23.73%
• 5Y*: -51.43%
• 10Y*: —

HRMY

• 1D: -0.18%
• 1M: -3.25%
• YTD: -25.28%
• 6M: 3.86%
• 1Y: -13.76%
• 3Y*: -5.04%
• 5Y*: -2.72%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

ALXO vs. HRMY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ALXO

ALXO Risk / Return Rank: 88
ALXO Sharpe Ratio Rank: 89
ALXO Sortino Ratio Rank: 90
ALXO Omega Ratio Rank: 83
ALXO Calmar Ratio Rank: 91
ALXO Martin Ratio Rank: 86

HRMY

HRMY Risk / Return Rank: 25
HRMY Sharpe Ratio Rank: 26
HRMY Sortino Ratio Rank: 25
HRMY Omega Ratio Rank: 24
HRMY Calmar Ratio Rank: 26
HRMY Martin Ratio Rank: 23

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ALXO vs. HRMY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for ALX Oncology Holdings Inc. (ALXO) and Harmony Biosciences Holdings, Inc. (HRMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ALXO	HRMY	Difference
Sharpe ratio Return per unit of total volatility	1.89	-0.33	+2.22
Sortino ratio Return per unit of downside risk	2.86	-0.18	+3.04
Omega ratio Gain probability vs. loss probability	1.31	0.97	+0.34
Calmar ratio Return relative to maximum drawdown	4.08	-0.46	+4.54
Martin ratio Return relative to average drawdown	8.57	-0.99	+9.56
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ALXO vs. HRMY - Sharpe Ratio Comparison

The current ALXO Sharpe Ratio is 1.89, which is higher than the HRMY Sharpe Ratio of -0.33. The chart below compares the historical Sharpe Ratios of ALXO and HRMY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	ALXO	HRMY	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.89	-0.33	+2.22
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.52	-0.05	-0.47
Sharpe Ratio (All Time) Calculated using the full available price history	-0.38	-0.09	-0.29

Correlation

The correlation between ALXO and HRMY is 0.24, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

ALXO vs. HRMY - Dividend Comparison

Neither ALXO nor HRMY has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

ALXO vs. HRMY - Drawdown Comparison

The maximum ALXO drawdown since its inception was -99.64%, which is greater than HRMY's maximum drawdown of -68.48%. Use the drawdown chart below to compare losses from any high point for ALXO and HRMY.

Drawdown Indicators

	ALXO	HRMY	Difference
Max Drawdown Largest peak-to-trough decline	-99.64%	-68.48%	-31.16%
Max Drawdown (1Y) Largest decline over 1 year	-50.46%	-34.49%	-15.97%
Max Drawdown (5Y) Largest decline over 5 years	-99.50%	-68.48%	-31.02%
Current Drawdown Current decline from peak	-98.21%	-54.10%	-44.11%
Average Drawdown Average peak-to-trough decline	-78.54%	-34.76%	-43.78%
Ulcer Index Depth and duration of drawdowns from previous peaks	24.03%	15.96%	+8.07%

Volatility

ALXO vs. HRMY - Volatility Comparison

ALX Oncology Holdings Inc. (ALXO) has a higher volatility of 18.66% compared to Harmony Biosciences Holdings, Inc. (HRMY) at 7.89%. This indicates that ALXO's price experiences larger fluctuations and is considered to be riskier than HRMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ALXO	HRMY	Difference
Volatility (1M) Calculated over the trailing 1-month period	18.66%	7.89%	+10.77%
Volatility (6M) Calculated over the trailing 6-month period	73.93%	31.01%	+42.92%
Volatility (1Y) Calculated over the trailing 1-year period	118.14%	41.98%	+76.16%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	99.42%	50.61%	+48.81%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	99.22%	52.82%	+46.40%

Financials